In some embodiments, the combination of one or more compounds 101-105 with the above-described fats, oils, or emulsions has a synergistic effect
Disclosures: Tae-Hwi Schwantes-An: Target RWE: Consultant, Kung-Hung Lin: Nothing to Disclose, Marco Abreu: Nothing to Disclose, Jingyi Tan: Nothing to Disclose, Xiuqing Guo: Nothing to Disclose, Katherine Yates: Nothing to Disclose, Luca Lotta: Nothing to Disclose, Niek Verweij: Nothing to Disclose, Rohit Loomba: Eli Lilly and Company: Consultant, Jerome Rotter: Nothing to Disclose, Naga Chalasani: Madrigal: Consultant, Zydus, Ipsen, Pfizer, Merck, Altimmune, GSK: Consultant, Exact Sciences: Grant/Research Support, NIH: Grant/Research Support 2566 PATHOGENIC VARIANTS ASSOCIATED WITH MONOGENIC DISORDERS OF DYSLIPIDEMIA IN PATIENTS WITH WELL CHARACTERIZED MASLD Tae-Hwi Schwantes-An 1 Eduardo Vilar-Gomez 1 Marco Abreu 1 Brent Neuschwander-Tetri 2 Miriam Vos 3 Jian Wang 4 Xiuqing Guo 5 Jingyi Tan 5 Robert A Hegele 4 Nicholas Davidson 6 George Hindy 7 Luca Lotta 7 Niek Verweij 7 Jerome Rotter 5 Naga Chalasani 8 , 1 Indiana University School of Medicine, 2 Saint Louis University, 3 Emory University, Children's Healthcare of Atlanta, 4 Robarts Research Institute, 5 Lundquist Institute, 6 Washington University Medical Center, 7 Regeneron, 8 Indiana University Medical Center Background: Dyslipidemia is common in patients with MASLD, and it can sometimes be due to monogenic disorders
Together, elevated iron levels and dysbiosis-induced oxidative stress and lipid peroxidation contribute to the induction of ferroptosis, thereby accelerating the progression of ALD
2019 [PMC free article: PMC6425411] [PubMed: 30949365] 61
